Skip to content
OpenCapital
Get started

Eikon Therapeutics, Inc. EIKN Net Interest Income

Net Interest Income at other companies

Republic Bancorp logo
Republic BancorpRBCAA
$90.45M-11.9%
Pathward Financial, Inc. logo
Pathward Financial, Inc.CASH
$125.12M-8.2%
German American Bancorp logo
German American BancorpGABC
$78.85M+18.4%
Stellar Bancorp logo
Stellar BancorpSTEL
$105.93M+6.7%
First Financial Bancorp logo
First Financial BancorpFFBC
$189.61M+27.0%
Customers Bancorp logo
Customers BancorpCUBI
$191.35M+14.3%

Other financials

Income statement

See full
Operating income-$87.3M-22.3%
Net income-$83.0M-21.6%
EPS (diluted)-$2.46+90.9%

Balance sheet

See full
Cash & equivalents$161.2M-21.2%
Total debt$254.8M—
Total equity$550.7M+186%
Total assets$850.8M—

Cash flow

See full
Operating cash flow-$89.8M-64.7%
CapEx$262.0K-98.8%
Free cash flow-$90.1M-17.1%

Valuation

See full
Market cap$514.86M—

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNet.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eikon Therapeutics, Inc. 's net interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eikon Therapeutics, Inc. 's net interest income?
Eikon Therapeutics, Inc. (EIKN) reported net interest income of $4.38M in Q1 2026.